
GeoVax's GEO-CM04S1 Demonstrates Superior T-Cell Responses in CLL Patients, DSMB Ends Comparator Arm After mRNA Vaccine Failure
GeoVax's next-generation COVID-19 vaccine GEO-CM04S1 generated significantly stronger and more durable T-cell responses than Pfizer-BioNTech's mRNA vaccine in chronic lymphocytic leukemia patients, leading to discontinuation of the comparator arm and highlighting its potential to address protection gaps for immunocompromised populations.
Read full story


























